Xenon Pharmaceuticals Stock Performance
| XENE Stock | USD 43.15 0.70 1.65% |
Xenon Pharmaceuticals has a performance score of 5 on a scale of 0 to 100. The firm maintains a market beta of 1.35, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Xenon Pharmaceuticals will likely underperform. Xenon Pharmaceuticals right now maintains a risk of 2.16%. Please check out Xenon Pharmaceuticals maximum drawdown, accumulation distribution, relative strength index, as well as the relationship between the semi variance and day typical price , to decide if Xenon Pharmaceuticals will be following its historical returns.
Risk-Adjusted Performance
5 of 100
Weak | Strong |
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Xenon Pharmaceuticals are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of rather conflicting basic indicators, Xenon Pharmaceuticals may actually be approaching a critical reversion point that can send shares even higher in December 2024. ...more
Actual Historical Performance (%)
One Day Return 1.65 | Five Day Return 7.71 | Year To Date Return (3.92) | Ten Year Return 253.4 | All Time Return 310.95 |
1 | Xenon Showcases Azetukalner Data at 15th European Epilepsy Congress | 09/09/2024 |
2 | Equities Analysts Offer Predictions for XENE FY2026 Earnings | 10/18/2024 |
3 | First Light Asset Management, LLC Increases Stake in Axogen Inc | 11/08/2024 |
4 | Xenon Pharma GAAP EPS of -0.81 in-line | 11/12/2024 |
5 | Xenon Pharmaceuticals Inc Q3 2024 Earnings Call Highlights Strategic Advancements and ... | 11/13/2024 |
6 | Xenon Pharmaceuticals Sees Unusually Large Options Volume | 11/14/2024 |
7 | Avenzo Therapeutics Announces Appointment of Patrick Machado, J.D. to Board of Directors as Independent Director | 11/20/2024 |
8 | Disposition of 3086 shares by Patou Gary of Xenon Pharmaceuticals at 13.48 subject to Rule 16b-3 | 11/22/2024 |
9 | Estimating The Intrinsic Value Of Xenon Pharmaceuticals Inc. | 11/25/2024 |
| Begin Period Cash Flow | 57.2 M | |
| Free Cash Flow | -150.9 M |
Xenon |
Xenon Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 4,015 in Xenon Pharmaceuticals on August 31, 2024 and sell it today you would earn a total of 300.00 from holding Xenon Pharmaceuticals or generate 7.47% return on investment over 90 days. Xenon Pharmaceuticals is currently generating 0.1375% in daily expected returns and assumes 2.164% risk (volatility on return distribution) over the 90 days horizon. In different words, 19% of stocks are less volatile than Xenon, and 98% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Xenon Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Xenon Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Xenon Pharmaceuticals, and traders can use it to determine the average amount a Xenon Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0636
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | XENE | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.16 actual daily | 19 81% of assets are more volatile |
Expected Return
| 0.14 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.06 actual daily | 5 95% of assets perform better |
Based on monthly moving average Xenon Pharmaceuticals is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Xenon Pharmaceuticals by adding it to a well-diversified portfolio.
Xenon Pharmaceuticals Fundamentals Growth
Xenon Stock prices reflect investors' perceptions of the future prospects and financial health of Xenon Pharmaceuticals, and Xenon Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Xenon Stock performance.
| Return On Equity | -0.27 | ||||
| Return On Asset | -0.19 | ||||
| Current Valuation | 2.65 B | ||||
| Shares Outstanding | 76.24 M | ||||
| Price To Earning | (1.75) X | ||||
| Price To Book | 4.12 X | ||||
| Price To Sales | 181.44 X | ||||
| Gross Profit | (96.33 M) | ||||
| EBITDA | (210.51 M) | ||||
| Net Income | (182.39 M) | ||||
| Cash And Equivalents | 788.24 M | ||||
| Cash Per Share | 12.66 X | ||||
| Total Debt | 10.9 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 57.86 X | ||||
| Book Value Per Share | 12.31 X | ||||
| Cash Flow From Operations | (145.33 M) | ||||
| Earnings Per Share | (2.81) X | ||||
| Market Capitalization | 3.29 B | ||||
| Total Asset | 964.8 M | ||||
| Retained Earnings | (665.14 M) | ||||
| Working Capital | 617.69 M | ||||
| Current Asset | 60.87 M | ||||
| Current Liabilities | 2.78 M | ||||
About Xenon Pharmaceuticals Performance
By analyzing Xenon Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Xenon Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Xenon Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Xenon Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (3.91) | (4.11) | |
| Return On Tangible Assets | (0.19) | (0.20) | |
| Return On Capital Employed | (0.23) | (0.24) | |
| Return On Assets | (0.19) | (0.20) | |
| Return On Equity | (0.20) | (0.21) |
Things to note about Xenon Pharmaceuticals performance evaluation
Checking the ongoing alerts about Xenon Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Xenon Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Net Loss for the year was (182.39 M) with loss before overhead, payroll, taxes, and interest of (96.33 M). | |
| Xenon Pharmaceuticals currently holds about 788.24 M in cash with (145.33 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.66. | |
| Xenon Pharmaceuticals has a very weak financial position based on the latest SEC disclosures | |
| Over 100.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from simplywall.st: Estimating The Intrinsic Value Of Xenon Pharmaceuticals Inc. |
- Analyzing Xenon Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Xenon Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Xenon Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Xenon Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Xenon Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Xenon Pharmaceuticals' stock. These opinions can provide insight into Xenon Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Xenon Stock analysis
When running Xenon Pharmaceuticals' price analysis, check to measure Xenon Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xenon Pharmaceuticals is operating at the current time. Most of Xenon Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Xenon Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xenon Pharmaceuticals' price. Additionally, you may evaluate how the addition of Xenon Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |